Reviva pharmaceuticals holdings, inc. reports full year 2021 financial results and recent business highlights

- topline data for pivotal phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023

RVPH Ratings Summary

RVPH Quant Ranking